ClinicalTrials.gg
CompletedNCT00547157Updated Mar 15, 2017Results posted

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

A Phase 2 interventional study of Panitumumab and Cisplatin in Cancer, Head and Neck Cancer and Oncology, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first line treatment for locally advanced squamous cell carcinoma for the head and neck (SCCHN). A formal hypothesis will not be tested in this trial; however, the treatment arm difference in LRC rates at 2 years will be estimated.

Read the detailed description

Primary Objective: To estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first line treatment for locally advanced squamous cell carcinoma for the head and neck (SCCHN).

Secondary Objectives: To estimate the difference between 2 treatment regimens (CRT vs PRT) on other measures of clinical benefit, including LRC, overall response rate (ORR), progression-free survival (PFS), overall survival (OS); and safety.

Tertiary Objectives: To estimate the difference in health-related quality of life (HRQoL) and performance status in subjects receiving PRT or CRT.

Exploratory Objectives: To investigate potential biomarker development based on assessment of blood and tumor and the proposed mechanism of actions of study drugs. In addition, to investigate the effect of genetic variation in cancer genes and drug target genes on SCCHN and subject response to study drugs (separate informed consent required).

Hypothesis: A formal hypothesis will not be tested in this trial; however, the treatment arm difference in LRC rates at 2 years will be estimated.

Study Design: This is a phase 2, open-label, randomized, multicenter study. Eligible subjects will be randomized in a 2:3 ratio to either of the following regimens:

Arm 1 CRT:

  • Accelerated fractionation RT: 70 to 72 Gy - delivered over 6 to 6.5 weeks
  • Cisplatin: 100 mg/m2 (given on days 1 and 22 of RT) or

Arm 2 PRT:

  • Accelerated fractionation RT: 70 to 72 Gy - delivered over 6 to 6.5 weeks
  • Panitumumab: 9.0 mg/kg Q3W (given on days 1, 22, and 43 of RT)
02

Conditions studied

  • Cancer
  • Head and Neck Cancer
  • Oncology
  • Squamous Cell Carcinoma

Keywords

  • head and neck
  • squamous cell carcinoma
  • radiotherapy
  • chemoradiotherapy
  • panitumumab
  • locally advanced head & neck cancer
  • EGFr
  • epidermal growth factor receptor
  • SCCHN
  • locally advanced SCCHN
  • HNC
  • epidermal growth factor
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 152 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

or cytologically confirmed SCC of the oral cavity, oropharynx, hypopharynx or larynx Stage III or Stage IVa-b (M0) disease according to the American Joint Committee on Cancer staging manual 6th edition (locally advanced) performance status of 0 or 1 Bidimensionally >/= 10 mm in at least 1 dimension

Exclusion criteria

Exclusion Criteria:

NO Primary tumor of the nasopharynx, sinuses, salivary gland, or skin NO Subjects requiring prophylactic tracheostomy NO Prior (or concomitant) (except non-melanomatous skin cancer or in situ cervical cancer), other than the study disease (SCCHN), unless treated with curative intent with no evidence of disease for >/= 3 years NO Prior treatment for locally advanced SSCHN NO Prior surgery for SCCHN (except nodal sampling or for study disease) NO Major surgery \</= 28 days before randomization or minor surgery \</= 14 days before randomization with the exception of feeding tube placement, dental extractions, central venous catheter placement, biopsies and nodal sampling

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Active comparator
    ARM 1 CRT

    Cisplatin plus RT

    Drug: Cisplatin

  • Experimental
    ARM 2 PRT

    Panitumumab plus RT

    Drug: Panitumumab

Interventions

  • Arm 2 consists of panitmumab plus RT

    Also known as: Panitumumab (drug)

  • Cisplatin

    Also known as: Cisplatin (Chemotherapy)

06

What researchers measure

Primary outcomes

  1. Local Regional Control Rate at 2 Years

    Kaplan-Meier estimate of Local regional control rate at 2 years. Local regional control rate will be measured according to the investigator's assessment of disease status based on all available data (ie, from clinical examination, radiologic assessments, pathology reports, and autopsy reports).

    Time frame: from study day 1 to 2 years

Secondary outcomes

  1. Duration of Local Regional Control

    Time from study day 1 to the date of first local-regional failure or to death due to any cause (whichever occurs first)

    Time frame: maximum follow up time 46.2 months

  2. Progression-free Survival

    Time from first dose date till disease progression or death

    Time frame: maximum follow up time 46.2 months

  3. Overall Survival

    Time from first dose date to death

    Time frame: maximum follow up time 46.2 months

  4. ORR by 6 Months - Central

    ORR is Objective Response Rate. Tumor assessments are based on central review of scans uisng a modification of the WHO criteria. Complete or partial response is considered as objective response.

    Time frame: From randomization to 6 months

  5. CRR by 6 Months - Central

    CRR is Complete Response Rate. Tumor assessments are based on central review of scans uisng a modification of the WHO criteria. Complete Response (CR) is defined as disappearance of all index lesions.

    Time frame: From randomization till 6 months

07

Results

Posted May 23, 2014

Participant flow

152 subjects were enrolled with 90 subjects randomized to panitumumab plus radiotherapy arm, and 62 subjects randomized to chemoradiotherapy arm.

Participant flow — Overall Study
MilestonePanitumumab Plus RadiotherapyChemoradiotherapy
Started9062
Completed4139
Not completed4923
Withdrew: Other10
Withdrew: Death3818
Withdrew: Withdrawal by subject31
Withdrew: Administrative decision32
Withdrew: Lost to follow-up42

Outcome measures

PrimaryLocal Regional Control Rate at 2 Years

Kaplan-Meier estimate of Local regional control rate at 2 years. Local regional control rate will be measured according to the investigator's assessment of disease status based on all available data (ie, from clinical examination, radiologic assessments, pathology reports, and autopsy reports).

Time frame:
from study day 1 to 2 years
Reported as:
Number · Proportion of Participants
Local Regional Control Rate at 2 Years
Proportion of ParticipantsPanitumumab Plus RadiotherapyChemoradiotherapy
Local Regional Control Rate at 2 Years0.51 (0.40 to 0.62)0.61 (0.47 to 0.72)
Statistical analysis
  • Panitumumab Plus Radiotherapy vs Chemoradiotherapy · Risk difference (rd): -0.09 · 95% CI -0.26 to 0.07difference is PRT - CRT
SecondaryDuration of Local Regional Control

Time from study day 1 to the date of first local-regional failure or to death due to any cause (whichever occurs first)

Time frame:
maximum follow up time 46.2 months
Reported as:
Median · months
Duration of Local Regional Control
monthsPanitumumab Plus RadiotherapyChemoradiotherapy
Duration of Local Regional Control25.1 (12.0 to 36.0)NA (14.4 to NA)
Statistical analysis
  • Panitumumab Plus Radiotherapy vs Chemoradiotherapy · Regression, Cox · p = 0.0601 · Hazard ratio (hr): 1.613 · 95% CI 0.980 to 2.656Hazard ratio is presented as panitumumab plus radiotherapy:chemoradiotherapy.
SecondaryProgression-free Survival

Time from first dose date till disease progression or death

Time frame:
maximum follow up time 46.2 months
Reported as:
Median · months
Progression-free Survival
monthsPanitumumab Plus RadiotherapyChemoradiotherapy
Progression-free Survival17.3 (12.0 to 27.0)NA (17.5 to NA)
Statistical analysis
  • Panitumumab Plus Radiotherapy vs Chemoradiotherapy · Regression, Cox · p = 0.0259 · Hazard ratio (hr): 1.731 · 95% CI 1.068 to 2.806Hazard ratio is presented as panitumumab plus radiotherapy:chemoradiotherapy.
SecondaryOverall Survival

Time from first dose date to death

Time frame:
maximum follow up time 46.2 months
Reported as:
Median · months
Overall Survival
monthsPanitumumab Plus RadiotherapyChemoradiotherapy
Overall Survival41.7 (27.2 to NA)NA (NA to NA)
Statistical analysis
  • Panitumumab Plus Radiotherapy vs Chemoradiotherapy · Regression, Cox · p = 0.1039 · Hazard ratio (hr): 1.593 · 95% CI 0.909 to 2.793Hazard ratio is presented as panitumumab plus radiotherapy:chemoradiotherapy
SecondaryORR by 6 Months - Central

ORR is Objective Response Rate. Tumor assessments are based on central review of scans uisng a modification of the WHO criteria. Complete or partial response is considered as objective response.

Time frame:
From randomization to 6 months
Reported as:
Number · Proporation of Participants
ORR by 6 Months - Central
Proporation of ParticipantsPanitumumab Plus RadiotherapyChemoradiotherapy
ORR by 6 Months - Central0.722 (0.618 to 0.812)0.767 (0.640 to 0.866)
Statistical analysis
  • Panitumumab Plus Radiotherapy vs Chemoradiotherapy · Regression, Logistic · p = 0.5744 · Odds ratio (or): 0.791 · 95% CI 0.342 to 1.785The odd ratio is defined as the odds of having an objective response in the panitumumab plus radiotherapy arm relative to the odds in the chemoradiotherapy arm.
  • Panitumumab Plus Radiotherapy vs Chemoradiotherapy · Difference in objective response rate: -0.044 · 95% CI -0.187 to 0.112Difference is objective response rate in the panitumumab plus radiotherapy arm minus the rate in the chemoradiotherapy arm.
SecondaryCRR by 6 Months - Central

CRR is Complete Response Rate. Tumor assessments are based on central review of scans uisng a modification of the WHO criteria. Complete Response (CR) is defined as disappearance of all index lesions.

Time frame:
From randomization till 6 months
Reported as:
Number · Proportion of Participants
CRR by 6 Months - Central
Proportion of ParticipantsPanitumumab Plus RadiotherapyChemoradiotherapy
CRR by 6 Months - Central0.144 (0.079 to 0.234)0.117 (0.048 to 0.226)
Statistical analysis
  • Panitumumab Plus Radiotherapy vs Chemoradiotherapy · Regression, Logistic · p = 0.8070 · Odds ratio (or): 1.278 · 95% CI 0.438 to 4.043The odd ratio is defined as the odds of having an objective response in the panitumumab plus radiotherapy arm relative to the odds in the chemoradiotherapy arm.
  • Panitumumab Plus Radiotherapy vs Chemoradiotherapy · Difference in complete response rate: 0.029 · 95% CI -0.103 to 0.141Difference is objective response rate in the panitumumab plus radiotherapy arm minus the rate in the chemoradiotherapy arm.

Adverse events

Collected over The median reporting period was around 74 days in the Panitumumab Plus Radiotherapy arm, and around 74 days in the Chemoradiotherapy arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus Radiotherapy—30/89 (33.7%)88/89 (98.9%)
Chemotherapy Plus Radiotherapy—25/62 (40.3%)61/62 (98.4%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventPanitumumab Plus RadiotherapyChemotherapy Plus Radiotherapy
Mucosal inflammationGeneral disorders6/896/62
DysphagiaGastrointestinal disorders7/893/62
Febrile neutropeniaBlood and lymphatic system disorders0/894/62
NeutropeniaBlood and lymphatic system disorders0/893/62
Weight decreasedInvestigations3/890/62
DehydrationMetabolism and nutrition disorders3/891/62
StomatitisGastrointestinal disorders2/890/62
Sudden deathGeneral disorders2/890/62
HyperbilirubinaemiaHepatobiliary disorders2/890/62
Skin infectionInfections and infestations2/890/62
Most frequent other events
Showing 10 of 51
Most frequent other events
EventPanitumumab Plus RadiotherapyChemotherapy Plus Radiotherapy
DysphagiaGastrointestinal disorders64/8939/62
Mucosal inflammationGeneral disorders54/8942/62
Radiation skin injuryInjury, poisoning and procedural complications47/8935/62
RashSkin and subcutaneous tissue disorders48/892/62
NauseaGastrointestinal disorders19/8927/62
OdynophagiaGastrointestinal disorders33/8922/62
Dry mouthGastrointestinal disorders30/8921/62
DysgeusiaNervous system disorders18/8921/62
ConstipationGastrointestinal disorders28/8915/62
VomitingGastrointestinal disorders14/8918/62

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panitumumab Plus RadiotherpyChemoradiotherapyTotal
Mean56.9 ± 8.357.4 ± 7.957.1 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus RadiotherpyChemoradiotherapyTotal
Female18725
Male7255127
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Panitumumab Plus RadiotherpyChemoradiotherapyTotal
Asian0000
Black or African American000
White8860148
Hispanic or Latino224
Radiotherapy Delivery Modality
Radiotherapy Delivery Modality(Participants)Panitumumab Plus RadiotherpyChemoradiotherapyTotal
IMRT493281
3D-CRT412970
Missing011
Primary Tumor Site
Primary Tumor Site(Participants)Panitumumab Plus RadiotherpyChemoradiotherapyTotal
Oropharynx/Larynx6644110
Oral Cavity/Hypopharynx241842
Nodal Status
Nodal Status(Participants)Panitumumab Plus RadiotherpyChemoradiotherapyTotal
N011718
N+7955134
Tumor Stage
Tumor Stage(Participants)Panitumumab Plus RadiotherpyChemoradiotherapyTotal
T1-3583997
T4322355
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesia R, Zhang A, Oliner KS, VanderWalde A. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15. PubMed 25596659 ↗
  • Mesia R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15. PubMed 25596660 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Dec 2011 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2007
First posted
Oct 22, 2007
Start
Nov 2007
Primary completionActual
Dec 2011
CompletionActual
Mar 2012
Results first posted
May 23, 2014
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00547157
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 22, 2007
Start date
Nov 2007
Primary completion
Dec 2011
Completion
Mar 2012
Results posted
May 23, 2014
Last update
Mar 15, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion